Audit: QRS - Methylene Blue for Health & Longevity

Audit conducted on 15/08/2026 02:32 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: protocol cells to ER Therapeutic Protocol (lines 372, 378, 382), time cells to ER lines 159/161 and 423, benefit and risk items to the ER tier headings, gates to Key Interactions & Contraindications (lines 327–350), monitoring rows verbatim to the ER biomarker table (lines 453–460), cadence to lines 447–449, qualitative items to lines 464–469.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges are carried through: “Where they occur” (time_2_sub), “generally avoided in reported protocols” (action_2_sub), “used only above roughly 60 mg daily” (action_3_sub), “claims rest on thin data” (at_a_glance).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Absolute contraindications stay absolute (pregnancy, G6PD deficiency, serotonergic drugs remain in the stop gate); ER cautions stay in the caution gate. No directional shift found.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from ER Key Interactions & Contraindications; risks only from Potential Risks & Side Effects; benefits only from Expected Benefits. No Benefit-Modifying Factors or Risk-Modifying Factors content appears in the gates.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, no citations, no NCT identifiers, no expert names and no brand names (ProvayBlue is not carried over). Only generic drug names, all present in the ER interaction bullets.
1.6	The QRS does not introduce new attributions.	🟢	No attribution appears anywhere in the sheet.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s reserved, evidence-weighted register; the at-a-glance mirrors the Conclusion’s framing of a narrow safe window and thin efficacy data.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric targets, thresholds and a single screening test (G6PD) give the reader concrete, actionable handles while the language stays neutral and non-alarmist.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as observed practice (“what reported protocols use”, “is standard given the long half-life”) rather than instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive verbs; monitoring entries are stated as ranges and reasons, not orders.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “should”, “recommend”, “advise” or equivalents in the sheet body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to unavoidable biomarker and drug-class names carried from the ER; the at-a-glance is fully plain-language.
2.8	Information is presented in a concise and very compact manner	🟢	Every item is a short noun phrase or clause; magnitudes, mechanisms and study details from the ER are stripped.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Sheet is built around self-directed screening, dosing and monitoring decisions, which is what this audience acts on.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Assumes willingness to obtain a quantitative G6PD assay, run an eight-marker laboratory panel and track daily blood pressure.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Depth of the monitoring panel and the medication-audit framing place it well beyond general-population material.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance states plainly that the memory, energy and aging claims rest on thin data, and time_1_sub marks the strongest benefit as hospital rescue therapy rather than something the low oral protocol delivers.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	Title and header use “Health & Longevity”; the string “anti-aging” does not occur.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Uses “1% aqueous oral solution”, “intravenous dose”, “adverse reactions”, “hemolytic anemia”, “hypersensitivity and anaphylactoid reactions”. No consumer-grade substitutes found.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings match [qrs_template] byte for byte (QRS lines 443, 487, 533, 563, 578, 608, 640, 644–646, 787 and the four <strong> tier labels).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 distinct template variables are present; the only additional names are the repeated marker_#_* rows and qualitative_item_# instances, which the template defines as repeatable patterns.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A full structural diff against [qrs_template] shows changes only inside spans covered by checklist items; the CSS block, the website="evidence_review" / website="audit" / website="full_review" spans and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section feeding the QRS is empty; every benefit tier, risk tier, gate list, monitoring row and qualitative item has ER content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1/2/3_label reproduce the ER Therapeutic Protocol bold labels verbatim (“Standard low-dose protocol”, “Best time of day”, “Single versus split dosing”); monitoring row labels reproduce the ER biomarker-table entries verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Where the ER supplies labels they are copied unchanged; the three time-to-effect labels are drawn from ER benefit headings and the ER’s own “Time to effect” bullet wording, as the ER supplies no bold label for those sub-facts.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; the ER’s “⚠️ Conflicted” marker on the Alzheimer’s benefit was correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Substantial per-section condensation applied: the ER biomarker table’s entire “Context/Notes” column is dropped, all magnitudes/effect sizes/citations are stripped from Benefits and Risks, the two-paragraph ER monitoring cadence is reduced to two sentences, and the ER’s eleven Therapeutic Protocol bullets are reduced to three cells. Item counts are fixed by 8.2, 9.2, 14.2 and 15.2 and cannot be reduced further.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; the comment opens immediately after <!doctype html> on line 1 and precedes <html lang="en"> on line 15.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the preamble text “QRS — Metadata (invisible, parsed by audit tooling)” sits before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are echoed by a visible element other than the independently specified header subline.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon; all other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: methylene_blue_2026-0815-0010_Opus_ER.md, matching the ER’s own filename frontmatter value.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0815-0222, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: methylene_blue_2026-0815-0010_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including the appended git_user and git_issue values; all clean.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 20: Methylene Blue for Health & Longevity - Quick Reference Sheet, matching the ER canonical_topic with the ampersand correctly encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 415: Methylene Blue for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 419: 08/15/2026, correctly derived from qrs_creation_date: 2026-0815-0222.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 423: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header block is byte-identical to the template apart from the three variable substitutions; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses the four load-bearing conclusions: approved use, thin efficacy data, narrow safe window set by interactions plus one screenable trait, and the dose-direction reversal that dictates low fixed dosing.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Maps to ER lines 491 (“cheap, long-established dye whose only approved medical use…”, “in memory, energy and slowed aging, the evidence thins”), 493 (“its effects reverse direction as the dose climbs”), 495 (“safe window is narrow and defined mainly by drug interactions and one screenable inherited trait”) and 359/372 (fixed low daily dose).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; G6PD is rendered as “one inherited red-cell enzyme deficiency” and methemoglobinemia as “a specific blood disorder”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, sample size or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimate appears; the only quantitative notion is the qualitative “safe window is narrow”.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items trace to ER lines 327, 329 and 345–350.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER “Populations who should avoid Methylene Blue” bullets are present, plus the two interaction bullets the ER marks “Absolute contraindication” (SSRIs/SNRIs, MAOIs and linezolid).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight discrete <li> elements at QRS lines 566–573.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing clauses are stripped throughout: “where drug exposure rises 192%” (kidney), “in whom the reducing pathway methylene blue depends on is absent” (reductase deficiency), “the antibiotic” (linezolid) and the “— absolute contraindication” tails. No dash-trailing content remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Retains the 60%-of-normal-mean G6PD threshold, the five-half-lives washout window, the eight-day breastfeeding window, the eGFR < 30 mL/min/1.73 m² threshold and both named drug-class example lists.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names several such populations and the section is correspondingly populated, so the constraint holds.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items trace to ER lines 331, 333, 335, 337, 339 and 341.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Exactly the six ER interaction bullets not marked “Absolute contraindication”; the SSRI/SNRI and MAOI bullets correctly appear only in the stop gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Six discrete <li> elements at QRS lines 581–598.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER consequence and mitigation clauses (“Consequence is serotonin toxicity”, “Mitigation is substitution with morphine…”, the CYP enzyme attributions, the prescribing-information citation) are all stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER example-drug list survives: opioids, triptans, serotonergic supplements, nitrates/PDE-5 inhibitors/NO boosters, and enzyme and P-glycoprotein substrates. Only the per-drug CYP attributions and the Hypericum perforatum Latin synonym are trimmed.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names six such interactions and the section is populated accordingly, so the constraint holds.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets at lines 372, 378 and 382.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing and single-versus-split administration are the three bullets that determine what is actually taken and when; the remaining ER bullets are background, attribution or modifier discussion.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects, so no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated: “0.5–1 mg/kg daily” with the 15–60 mg / 1% aqueous solution detail, “Morning” with the early-afternoon cut-off, and “Single morning administration” with the roughly 60 mg splitting threshold.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Methemoglobinemia reversal (ER line 159/161), cognitive and attentional effects and mood ratings (ER line 423) are the only onset windows the ER states explicitly.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High tier (Reversal of Acquired Methemoglobinemia) then the two Low-tier benefits, in the same order the ER lists them within the Low tier.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist in the ER, so no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated: “Within minutes” / IV rescue dose, “Within one hour” / single dose and gone within a day, “Weeks” / took weeks to separate from control.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information (lines 159 and 423), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All nine entries are the ER’s own benefit sub-headings from lines 157–209.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at QRS lines 535, 538, 544 and 551.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Every “Magnitude” line, PMID link and mechanistic sentence from the ER is stripped; only the bare benefit statements remain.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefit item; the ER’s “⚠️ Conflicted” marker on the Alzheimer’s heading is also dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All thirteen entries are the ER’s own risk sub-headings from lines 233–309.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at QRS lines 610, 616, 623 and 629.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Boxed-warning discussion, incidence figures, mechanism sentences and all PMID links are stripped; only the bare risk statements remain.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risk item; the ER’s inline glosses such as “(painful or difficult urination)” and “(brief involuntary muscle jerks)” are not carried over.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table and cadence derive from the ER Monitoring Protocol & Defining Success section, lines 447–460.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER table rows are present in ER order: G6PD activity, complete blood count with reticulocytes, methemoglobin by co-oximetry, total and indirect bilirubin, eGFR and creatinine, ALT and AST, resting blood pressure, serum potassium and magnesium — each with the ER’s Optimal Functional Range and Why Measure It text.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Populated at QRS lines 776–781 with the ER’s front-loaded cadence: baseline, daily blood pressure for week one, CBC and bilirubin at 4 weeks, full panel at 3 months then every 6 months, dose increases resetting the 4-week check, methemoglobin only above 1 mg/kg.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items derive from the ER’s “Qualitative markers tracked alongside the laboratory panel” list, lines 464–469.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are present in ER order: sleep onset and night waking, mental clarity and sustained attention, agitation/restlessness/jaw clenching/tremor, exercise tolerance and perceived exertion, degree of discoloration, and phototoxic skin signs.

Issues 15/08/2026 02:32

Pass rate 100.00%. No issues found.